louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00097578: A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma
Official title: An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Adenocarcinoma
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Colorectal Cancer
Lead sponsor: Genentech, Inc.
Sponsor class: INDUSTRY
First posted: 2004-11-25
Enrollment: 1953
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Sites were selected primarily from community-based oncology practices geographically distributed across the United States.

Brief summary: This is an observational study designed to follow patients with metastatic or locally advanced and unresectable colorectal cancer who are receiving Avastin in combination with chemotherapy and whose cancer has been either previously untreated or treated \<=4 months prior to enrollment.


Eligibility criteria: Inclusion Criteria:

* Signed Informed Consent and Authorization document
* Metastatic, or locally advanced and unresectable, adenocarcinoma of the colon or rectum
* Receiving Avastin as a component of first-line chemotherapy
* First-line chemotherapy plus Avastin initiated \<=4 months prior to enrollment in the study

Exclusion Criteria:

* Patients who have contraindications for treatment with Avastin (see the Avastin Package Insert) or who would incur excessive risks with Avastin treatment are ineligible for this study.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: South San Francisco
country: United States
facility: Genentech Central Contact
state: California
Study officials:
affiliation: Genentech, Inc.
name: Eric Hedrick, M.D.
role: STUDY_DIRECTOR
References:
citation: Kabbinavar FF, Flynn PJ, Kozloff M, Ashby MA, Sing A, Barr CE, Grothey A. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study. Eur J Cancer. 2012 May;48(8):1126-32. doi: 10.1016/j.ejca.2012.02.052. Epub 2012 Mar 15.
Clinical trial NCT06667778: Osseodensification in Enhancing Implant Stability and Ridge Expansion in Esthetic Region
Official title: Effectiveness of Osseodensification in Enhancing Implant Stability and Ridge Expansion in Esthetic Region (a Randomized Controlled Clinical Trial)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dental Implant
Bone Expantion
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2024-10-31
Enrollment: 18
Sex: ALL
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Dental implants supported restorations have been widely accepted as one of the treatment modalities to replace missing teeth and to restore human masticatory function. Successful osseointegration from the clinical standpoint is a measured by implant stability, which occurs after implant integration. Osseodensification is a bio-mechanical site preparation technique. It utilizes a multi-fluted densifying bur technology that creates and expands a pilot hole without excavating significant amounts of bone tissue through a unique, highly controllable, fast, and efficient procedure with minimal heat elevation.

Aim of the study: Is to evaluate and compare the efficacy of using osseodensification compared to conventional bone expansion in implant stability and ridge expansion.


Eligibility criteria: Inclusion Criteria:

* Missing maxillary anterior tooth, having moderate horizontal ridge defect in which the alveolar ridge width is( 3-4) mm, and its height is not less than 10 mm.
* Presence of adequate keratinized mucosa.
* Patients with good oral hygiene.
* Patients are free from any systemic diseases that might affect healing.
* Presence of adequate inter-occlusal and mesiodistal space that permits placement of fixed prosthesis.

Exclusion Criteria:

* Heavy smokers and bad oral hygiene patients.
* Medically compromised patients that affecting placement of implant.
* Alcohol or drug abuse.
* Pregnant women.
* Patients suffering from osteoporosis.
* Current chemotherapy or radiotherapy.

Primary outcomes:
measure: Change in implant stability
timeFrame: Baseline and 16 weeks
Secondary outcomes:
measure: Change in bone density
timeFrame: Baseline and 16 weeks
measure: Change in ridge expansion
timeFrame: Baseline and 16 weeks
measure: Change in bone loss
timeFrame: Baseline and 16 weeks
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Outpatient Clinic of Periodontology and Oral medicine Department, Faculty of Dentistry, Alexandria University, Egypt
Study officials:
References:
Clinical trial NCT02951078: A Study of Comparing Effects of Thulium Laser en Bloc Resection and Electrical Transurethral Resection of the Non-muscle Invasive Bladder Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Bladder Cancer
Lead sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Sponsor class: OTHER
First posted: 2016-11-01
Enrollment: 172
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is to verify the short-term efficacy and long-term prognosis of thulium laser resection compared with conventional transurethral resection of non-muscular invasive bladder cancer. Half of participants will receive thulium laser resection of bladder cancer, while the other half will receive electrical transurethral resection of bladder cancer.


Eligibility criteria: Inclusion Criteria:

1. Pathological or histological diagnosis of primary non-muscle invasive bladder urothelial carcinoma (TaTisT1);
2. Imaging examinations showed the bladder muscle has not been affected, no lymph node metastasis or distant metastasis;
3. Patients who agree to TURBT surgery, and will be effected to the postoperative follow-up treatment such as conventional infusion after the operation;
4. Function of main organs (heart, liver, lung, kidney) should be normal, PS score 0-2;
5. Bladder capacity≥ 200ml.

Exclusion Criteria:

1. Find distant metastasis ,infiltration of the surrounding organs or relapse before operation.Metastatic bladder cancer or other cancers involve the bladder;
2. Received chemotherapy or BCG perfusion therapy in the nearly 3 months;
3. Patients who can not tolerate the serious side effects during the bladder perfusion treatment process (bladder irritation and other symptoms);
4. Patients during pregnancy ,critical care patients and patients who have other cases of surgical contraindications.Such as serious cardiovascular disease,coagulation abnormalities,non-transitional epithelial tumors( such as adenocarcinoma and squamous cell carcinoma),acute cystitis,can not be supine because of spinal deformity,untreated urethral stricture.

Primary outcomes:
measure: The residual rate of tumor in the second operation of the two surgical methods
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03242278: Real-world Dosing Patterns of Rivaroxaban in the United States
Official title: Real-world Dosing Patterns of Rivaroxaban in the United States (RIVA-D)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Atrial Fibrillation
Keywords: Non-valvular atrial fibrillation (NVAF)
Prevention
Stroke
Lead sponsor: Bayer
Sponsor class: INDUSTRY
Collaborators: name: Janssen Research & Development, LLC
First posted: 2017-08-08
Enrollment: 12507
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with non-valvular atrial fibrillation (NVAF)

Brief summary: The primary objective is to assess the proportion of Non-valvular atrial fibrillation (NVAF) patients receiving the standard dose of 20 mg of rivaroxaban or the reduced dose of 15 mg of rivaroxaban.

The secondary objective is to determine if dosing patterns for rivaroxaban may be influenced by baseline chronic kidney disease (CKD) status (as a proxy for measured baseline renal function).


Eligibility criteria: Inclusion Criteria:

* NVAF (non-valvular atrial fibrillation) will be defined as the occurrence of 2 or more inpatient or outpatient claims with International Classification of Disease ICD-9 427.31 as the diagnosis code at any time in the patient's data history prior to inclusion
* Patients will be required to have 180 days of enrollment for the assessment of baseline characteristics
* CHA2DS2-Vasc score ≥2 during the 180 days prior to index rivaroxaban use baseline period
* Evidence of continuous enrollment in MarketScan during 180 days before the date of the first prescription of rivaroxaban

Exclusion Criteria:

* Patients \<18 years of age
* Patients with valvular AF (atrial fibrillation)
* Pregnancy
* Malignant cancers
* Transient cause of AF
* Patients with VTE (Venous thromboembolism), pulmonary embolism or DVT (Deep Vein Thrombosis)
* Patients with major surgery defined as hip or knee replacement
* Prescriptions of OACs (Oral anticoagulants) (apixaban,warfarin, dabigatran, rivaroxaban) before index date
* Prescription of more than one OAC on the index date

Primary outcomes:
measure: Number of NVAF patients receiving 20 mg Rivaroxaban
timeFrame: At baseline
measure: Number of NVAF patients receiving 15 mg Rivaroxaban
timeFrame: At baseline
Secondary outcomes:
measure: Baseline renal function
timeFrame: At baseline
Other outcomes:
Locations:
city: New York
country: United States
state: New York
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT01054378: Diaphragmatic Movement Before and After Stellate Ganglion Block : A Ultrasonographic Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Head Pain
Neck Pain
Shoulder Pain
Arm Pain
Neural Sensory Hearing Loss
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2010-01-22
Enrollment: 43
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The temporary diaphrgmatic dysfunction will occur after stellate ganglion block(SGB) and will be easily detected by M-mode ultrasonography


Eligibility criteria: Inclusion Criteria:

* ASA class I-II patients who have head and neck pain or shoulder pain or sudden sensory neural hearing loss

Exclusion Criteria:

* coagulopathy, pulmonary disease, neuropathy

Primary outcomes:
measure: The amplitude of diaphragm movement before and after SGB during quiet breathing, deep breathing and voluntary sniff, inspiratory time and expiratory time, oxygen saturation
timeFrame: The ultrasonographic evaluation will take place just before and 30 minutes after stellate ganglion block.
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Severance Hospital, Yonsei University College of Medicine
Study officials:
affiliation: Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Korea
name: Duck Mi Yoon
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03563378: Effects of Intraoperative Normal Saline vs Lactated Ringer on Outcomes in Pediatric Liver Transplantation
Official title: Effects of Intraoperative Normal Saline vs Lactated Ringer on Outcomes in Pediatric Liver Transplantation: A Double-blind Randomized Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Biliary Atresia Intrahepatic Syndromic Form
Lead sponsor: RenJi Hospital
Sponsor class: OTHER
First posted: 2018-06-20
Enrollment: 200
Sex: ALL
Minimum age (years): 3
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Lactated Ringer(LR) has been extensively used to maintain and replace intravascular volume in a variety of anesthetic procedures. However, the utility of LR in pediatric with hepatic failure undergoing liver transplantation is unclear, because addition of exogenous lactate may increase lactate concentration. In addition,large amounts of normal saline(NS) which does not contain lactate can induce a hyperchloremic metabolic acidosis and have been asociated with adverse effects on kidney injury, coagulation, and death. Accordingly, the investigators performed a double-blinded randomized trial comparing the effects of intraoperative NS or LR on outcomes in pediatric receiving Liver transplantation.


Eligibility criteria: Criteria

Inclusion Criteria:

1. Pediatric patients between the age of 3 month and 6 years
2. Scheduled for living donor liver transplantation

Exclusion Criteria:

1. Re-transplantation
2. Combined liver and kidney transplantation
3. Congenital heart disease
4. Refused to participate the study

Primary outcomes:
measure: Change in lactate level of the lactated ringer group compared to the normal saline group
timeFrame: up to 3 days after surgery
Secondary outcomes:
measure: Length of mechanical ventilation
timeFrame: up to 30 days after surgery
measure: ICU stay
timeFrame: up to 30 days after surgery
measure: 30 day mortality
timeFrame: up to 30 days after surgery
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Renji Hospital
state: Shanghai
Study officials:
affiliation: Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
name: qi lu, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05788978: Endometriosis Self-Care Behaviors Scale
Official title: Endometriosis Self-Care Behaviors Scale
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Endometriosis
Self Care
Behavior
Nursing Role
Lead sponsor: Marmara University
Sponsor class: OTHER
First posted: 2023-03-29
Enrollment: 400
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The research will be completed with a minimum of 200 women or a maximum of 420 women diagnosed with endometriosis.

Brief summary: In this study, it was aimed to develop a reliable and valid scale to measure the self-care behaviors of women with endometriosis.

Detailed description: In this study, it was aimed to develop a reliable and valid scale to measure the self-care behaviors of women with endometriosis.This research is of methodological type.Data will be collected by using "Participant Description Questionnaire" and "Self-Care Behaviors Scale in Endometriosis".

Eligibility criteria: Inclusion Criteria:

* Reproductive age,
* Diagnosed with endometriosis,
* Having no medical or gynecological problems other than endometriosis,
* Able to read and write,
* Not pregnant,
* No barriers to communication,
* Not diagnosed with a psychiatric illness,
* Volunteer to participate in the study,
* Women who can speak and understand Turkish will be included.
* Followed for at least 6 months,
* Having symptoms related to endometriosis,

Exclusion Criteria:

• Women who incomplete in the data collection forms incompletely will be excluded from the study.

Primary outcomes:
measure: Self-Care Behaviors Scale in Endometriosis
timeFrame: 9 months
Secondary outcomes:
Other outcomes:
Locations:
city: Maltepe
country: Turkey
facility: Hamide Arslan Tarus
state: İ̇stanbul
Study officials:
References:
Clinical trial NCT02117778: Comparison of Pulmonary Function and Efficacy of Different Nerve Block Catheters for Shoulder Surgery
Official title: A Comparative Pulmonary Function Study of Continuous Supraclavicular, Suprascapular, and Interscalene Nerve Catheters After Total Shoulder Arthroplasty
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Post-Operative Pain
Lead sponsor: Benaroya Research Institute
Sponsor class: OTHER
First posted: 2014-04-21
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is designed to evaluate lung function and pain control of continuous supraclavicular versus suprascapular versus interscalene nerve catheters in subjects undergoing total shoulder replacement. The investigators hypothesize that all three groups would have similar pain control; the supraclavicular and suprascapular groups may have better lung function.


Eligibility criteria: Inclusion Criteria:

* Unilateral total shoulder arthroplasty
* ASA physical status I-III
* \>18 years old
* Non-pregnant (or lactating)
* Consent to participate in the study

Exclusion Criteria:

* Refusal to participate
* \< 18 years old
* Chronic opioid use
* Localized infection
* Pregnancy or lactating
* Pre-existing coagulopathy
* Allergy to ultrasound gel or local anesthetics
* Diaphragmatic dysfunction

Primary outcomes:
measure: Lung function
timeFrame: Post-Operative Day 1
Secondary outcomes:
measure: Pain
timeFrame: Post Operative Day 1
measure: Opioid Consumption
timeFrame: Post Operative Day 1
measure: Sensory and Motor Function
timeFrame: Post Operative Day 1
Other outcomes:
Locations:
city: Seattle
country: United States
facility: Virginia Mason Medical Center
state: Washington
Study officials:
affiliation: Physician
name: David Auyong, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04811378: HaemoCerTM Application in Breast Cancer Surgery
Official title: Randomised Controlled Trial: HaemoCerTM Versus no HaemoCerTM in Breast Cancer Surgery to Reduce Postoperative Drainage Output
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Neoplasm Female
Mastectomy, Segmental
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2021-03-23
Enrollment: 136
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: HaemoCer is a hemostatic agent to control bleedings during surgical procedures by accelerating natural hemostasis and is frequently applied during breast conserving surgery in women with breast cancer. There is however no adequate data available on the efficacy of HaemoCer regarding seroma formation or drainage output. The objective of this study is to investigate whether the intraoperative application of haemostatic powder (HaemoCer) in breast-conserving surgery in breast cancer patients reduces the postoperative drainage output and number of days until drain removal (number of hospitalization days).


Eligibility criteria: Inclusion Criteria:

* Patients with breast cancer undergoing breast-conserving surgery
* No previous breast-conserving surgery on the same site
* ≥ 18 years age
* no current pregnancy
* Informed consent

Exclusion Criteria:

Patients with previous breast-conserving surgery on the same site

-

Primary outcomes:
measure: Total volume of postoperative drained fluid (per breast)
timeFrame: 7 days
measure: Number of days until drain removal (n)
timeFrame: 7 days
Secondary outcomes:
measure: Total volume of postoperative drained fluid from the axillary fossa in case of axilla surgery (sentinel lymphonodectomy, axillary dissection)
timeFrame: 7 days
measure: Rate of immediate postoperative infection on the breast surgery site
timeFrame: 7 days
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Medical University of Vienna
Study officials:
affiliation: Medical University of Vienna
name: Christian Singer, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03503578: EEG Studies of Sevoflurane-Induced General Anesthesia
Official title: Electroencephalogram Studies of Induction and Recovery From Sevoflurane-Induced General Anesthesia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Anesthesia
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2018-04-20
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The investigators are performing this research study to find out how and where the anesthetic drugs sevoflurane and ketamine act in the brain. Sevoflurane and ketamine are anesthetics (a drug or agent used to decrease or eliminate the feeling of pain by causing unconsciousness). The investigators will study the brain using a machine that records the brain's electrical activity, called an electroencephalogram (EEG).

Detailed description: During this research study, participants will receive sevoflurane, and sevoflurane and ketamine together, at a high enough dose to induce general anesthesia (make study participants "fall asleep"). During one visit participants will receive only sevoflurane; during another visit participants will be given both sevoflurane and ketamine together. The investigators will record EEG the entire time. The investigators will also ask some questions related to pain and cognitive function.

Eligibility criteria: Inclusion Criteria:

* Between the ages of 18 and 50
* Normal body weight and habitus, BMI ≤ 30
* Non-smoker
* American Society of Anesthesiologists (ASA) physical status classification P1

Exclusion Criteria:

* Chronic health conditions

Primary outcomes:
measure: Frequencies At Which Changes in Alpha, Theta, and Slow-Delta Wave Power Were Observed From Baseline During Sevoflurane-induced General Anesthesia
timeFrame: Approximately 60 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
References: